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G protein-coupled receptor kinase 2 (GRK2) is a central signaling node involved in the 
modulation of many G protein-coupled receptors (GPCRs) and also displaying regulatory 
functions in other cell signaling routes. GRK2 levels and activity have been reported to 
be enhanced in patients or in preclinical models of several relevant pathological situations, 
such as heart failure, cardiac hypertrophy, hypertension, obesity and insulin resistance 
conditions, or non-alcoholic fatty liver disease (NAFLD), and to contribute to disease 
progression by a variety of mechanisms related to its multifunctional roles. Therefore, 
targeting GRK2 by different strategies emerges as a potentially relevant approach to treat 
cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which 
are frequently interconnected and present as co-morbidities.
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INTRODUCTION
G protein-coupled receptor kinases (GRKs) were originally identified as key regulators of G protein-
coupled receptor (GPCR) function. GPCRs are activated by a wide variety of stimuli and comprise 
the largest family of membrane receptors. GPCRs are crucially involved in a multitude of physiological 
process, and their dysregulation contributes to many diseases, having thus become the targets of 
~35% of prescription drugs (Sriram and Insel, 2018). A fundamental characteristic of GPCR biology 
is that agonist-stimulated receptors, in addition to trigger activation of heterotrimeric G proteins 
and their classical downstream effectors, are specifically phosphorylated by GRKs, which in turn 
promotes binding of β-arrestin proteins to GPCRs thus inhibiting further interactions with G proteins, 
a process termed desensitization. Moreover, the fact that β-arrestins act as scaffold for proteins of 
the endocytic machinery and for many other signal transduction partners leads to transient receptor 
internalization and to a second wave of G protein-independent GPCR signaling cascades based on 
β-arrestin-orchestrated signalosomes. Therefore, GRK dosage and activity is a key feature that 
determines the extent of GPCR desensitization and internalization and the balance between G 
protein- and β-arrestin-dependent branches of GPCR signaling [reviewed in (Ranjan et  al., 2016; 
Smith and Rajagopal, 2016; Chen et  al., 2018)].
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The mammalian GRK family entails seven members classified 
into three subfamilies: visual GRKs (GRK1, also known as 
rhodopsin kinase, and GRK7), the GRK2 subfamily (GRK2 
and GRK3), and the GRK4 subfamily (GRK4, GRK5 and 
GRK6). GRK2, 3, 5, and 6 are ubiquitously expressed at varying 
levels, whereas GRK4 displays a more restricted tissue expression 
pattern and GRK1 and 7 are primarily present in specific 
retinal cells (Ribas et  al., 2007; Mushegian et  al., 2012; Watari 
et  al., 2014). Importantly, accumulating evidence indicates that 
GRKs can act as signal transducers by themselves, displaying 
a repertoire of substrates and/or interacting partners beyond 
GPCR and also a more general regulatory role in a variety 
of signaling processes (Penela et  al., 2010b; Mushegian et  al., 
2012; Watari et  al., 2014; Nogues et  al., 2017).
This multifunctionality is particularly evident for GRK2, which 
shows a complex array of non-GPCR substrates and cellular 
interactors, including receptor tyrosine kinases and their downstream 
molecules (EGFR, PDGFR, IRS1), signal transduction kinases 
(p38Mapk, AMPK, PI3K/Akt, MEK1), G protein subunits and 
modulators (Gαq, Gβγ, phosducin, RhoaA, RalA, EPAC1), 
transcription factors and their regulatory proteins (Smad2/3, IκBα), 
cytoskeletal proteins and modulators (ezrin, tubulin, GIT1, HDAC6), 
ubiquitin ligases (Mdm2, Nedd4–2), or different enzymes relevant 
for signaling (Pin1, eNOS) [reviewed in (Penela et  al., 2010b; 
Evron et  al., 2012; Mushegian et  al., 2012; Nogues et  al., 2017; 
Mayor et al., 2018)]. Moreover, altered GRK2 levels and functionality 
have been found in patient samples and/or in animal models of 
relevant pathological situations such as heart failure, hypertension, 
obesity and insulin resistance-related situations, non-alcoholic fatty 
liver disease (NAFLD), pain, inflammation, and some types of 
cancer, where anomalous GRK2 dosage or activity appears to 
contribute to disease progression via cell type and context-specific 
molecular mechanisms (Mushegian et al., 2012; Penela et al., 2014; 
Gurevich et  al., 2016; Hullmann et  al., 2016; Cannavo and Koch, 
2018; Cruces-Sande et  al., 2018; Mayor et  al., 2018; Nogues et  al., 
2018; Wang et al., 2018). Interestingly, several cardiovascular diseases 
as well as obesity and type 2 diabetes-related disorders, clinical 
conditions often interrelated as co-morbidities, converge in displaying 
increased GRK2 levels, pointing at the inhibition of GRK2 as an 
attractive therapeutic target. We  summarize in this review the 
physiopathological roles of GRK2 in cardiovascular and metabolic 
diseases and focus on potential strategies to downregulate GRK2 
functions based on our current knowledge about the structural 
features and mechanisms of regulation of this protein.
MOLECULAR MECHANISMS 
CONTROLLING GRK2 ACTIVATION  
AND FUNCTIONALITY
As the rest of the GRK isoforms, GRK2 is a multidomain 
protein organized in several domains and regions. The elucidation 
of the structure of GRK2 alone (Lodowski et  al., 2005) in 
complex with Gβγ subunits (Lodowski et  al., 2003) or with 
both Gβγ and Gαq subunits (Tesmer et  al., 2005) and the 
comparison with the available structures of other GRKs (Komolov 
and Benovic, 2018) has provided key insights into GRK2 
activation mechanisms. All GRKs are serine/threonine kinases 
that belong to the large AGC kinase family and share a catalytic 
domain displaying the characteristic bilobular fold of protein 
kinases, with high similarity to other AGC members, such as 
PKA, PKB, and PKC (Pearce et  al., 2010). This catalytic core 
is preceded by a domain displaying homology to RGS proteins 
(thus termed RH domain) that, in the case of GRK2 subfamily 
members, has been shown to specifically interact with Gαq/11 
subunits, thus blocking its interaction with their effectors 
(Carman et  al., 1999; Sanchez-Fernandez et  al., 2016). The 
RH domain displays at its far N-terminus a N-terminal helix 
(αN) characteristic of GRKs and important for receptor 
recognition. The C-terminal region is more variable among 
GRKs, but in all cases it is key for the localization to the 
plasma membrane. The C-terminal region of GRK2 and GRK3 
contains a pleckstrin homology domain (PH) that able to 
interact with membrane lipids such as the phospholipid PIP2 
and also with free Gβγ subunits (Homan and Tesmer, 2014; 
Nogues et  al., 2017) (Figure 1).
Importantly, GRKs show mechanisms of activation that are 
different to those of AGC kinases. In most AGC kinases, 
transitions from inactive to active conformations imply 
phosphorylation of regulatory motifs at the activation segment/
loop located in the large kinase lobe and at the hydrophobic 
motif found C-terminal to the small kinase lobe. Phosphorylation 
of these sites directs the closure of catalytic lobes and stabilizes 
the active conformation of the critical αC helix (Pearce et  al., 
2010). However, such phosphorylated regulatory motifs are 
absent in GRK2, and this protein thus requires conformation-
induced rearrangements to become active. GRK2 activation is 
based on the dynamic interactions of its αN-helix and the RH 
and PH domains among themselves and with activating partners 
such as agonist-occupied GPCR, Gβγ subunits, and PIP2, 
eventually leading to allosteric rearrangement of the functionally 
relevant AST loop and kinase domain closure (Homan and 
Tesmer, 2014; Nogues et al., 2017; Komolov and Benovic, 2018).
The recent co-crystallization of GRK5 with the β2AR (Komolov 
et  al., 2017) indicates that GRKs would display high structural 
plasticity, with large conformational changes in the GRK5 RH/
catalytic domain interface upon GPCR binding. In this model, 
the RH domain would serve as a docking site for GPCRs and 
help kinase activation via transient contacts of the RH bundle 
and kinase subdomains (Komolov and Benovic, 2018). Other 
studies support an important role for the RH domain of GRKs 
in GPCR interaction (Dhami et  al., 2004; Baameur et  al., 2010, 
2014; He et al., 2017). In addition to the RH domain, the αN-helix 
is also relevant to stabilize the kinase domain closure in a process 
regulated by GPCR binding (Singh et  al., 2008; Pao et  al., 2009; 
Boguth et  al., 2010; Beautrait et  al., 2014). Additionally, other 
motifs located within the catalytic domain of GRK2 might also 
participate in GPCR binding (Gan et  al., 2000, 2004).
The identification of residues and regions critical for receptor 
docking and/or allosteric kinase activation may help understand 
the preferential modulation of GPCR by certain GRKs and 
also guide the design of inhibitory strategies. On the other 
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hand, although the current model explains how closure of the 
kinase domain and subsequent GRK2 activation is achieved 
in a GPCR and Gβγ/phospholipid-dependent manner, it is 
important to ascertain how GRK2 might be activated to trigger 
phosphorylation of the increasing and heterogeneous repertoire 
of non-GPCR and non-membrane GRK2 substrates.
In this regard, it has been shown that GRK2 functionality 
can be  influenced by post-translational modifications in both 
the RH domain and the C-terminal region of the kinase (Penela 
et  al., 2010a, 2014; Lafarga et  al., 2012; Nogues et  al., 2017). 
GRK2 can be  phosphorylated by c-Src or EGFR on tyrosine 
residues located in the αN-helix (Tyr13) and within the RH 
region (Tyr-86 and Tyr-92), leading to enhanced catalytic activity 
toward both membrane receptors and soluble substrates (Sarnago 
et  al., 1999; Penela et  al., 2003; Chen et  al., 2008; Sun et  al., 
2017), suggesting an allosteric effect on the kinase domain 
via contacts of these residues with the AST region in the 
kinase lobes (Beautrait et al., 2014). On the other hand, second 
messenger-governed kinases, such as PKA and PKC, respectively, 
phosphorylate GRK2 at Ser685 enhancing its ability to bind 
to Gβγ and the activated GPCR (Cong et  al., 2001) or on 
Ser29 to increase GRK2 activity toward GPCR but not soluble 
peptides (Krasel et  al., 2001).
Phosphorylation of GRK2 at Ser670 by different kinases 
such as ERK1/2 (Elorza et  al., 2003) or CDK2 (Penela et  al., 
2010c) appears to play a very relevant modulatory role. This 
residue lies at the far C-terminus of GRK2 within the 
Gβγ-binding domain, and its phosphorylation impairs the 
interaction with Gβγ subunits, thus hindering GRK2 
translocation to the plasma membrane and activity toward 
GPCR (Pitcher et  al., 1999; Elorza et  al., 2000). Strikingly, 
GRK2 Ser670 phosphorylation can promote changes in substrate 
specificity, association with partners and subcellular localization. 
Stimuli or context-specific ERK1/2-dependent GRK2 Ser670 
phosphorylation is required to enable GRK2 to phosphorylate 
HDAC6 (Lafarga et  al., 2012; Nogues et  al., 2016), disrupts 
GRK2 interaction with GIT1 (Penela et  al., 2008), or directs 
localization to the mitochondrial outer membrane via enhanced 
interaction with the chaperone Hsp90 (Chen et  al., 2013). 
Thus, S670 phosphorylation plays a central role in the 
modulation of GRK2 functional features.
As for other mechanisms that able to control GRK2 activity, 
GRK2 can undergo S-nitrosylation of the Cys residue 340 
within its core catalytic domain, obstructing kinase activity 
toward GPCRs (Whalen et  al., 2007). On the other hand, 
GRK2 binds to clathrin, caveolin, or RKIP, which appear to 
participate in keeping GRK2 activity at bay at specific cellular 
locations (Gurevich et  al., 2012; Schmid et  al., 2015).
Finally, GRK2 expression levels are tightly regulated by a 
variety of mechanisms. GRK2 is rapidly degraded by the proteasome 
pathway in both basal and GPCR-stimulated conditions (Penela 
et al., 1998; Penela et al., 2003). GRK2 ubiquitination and turnover 
is enhanced by GPCR activation through complex mechanisms 
encompassing combined phosphorylation of GRK2 by c-Src and 
MAPK in a β-arrestin-dependent manner (Penela et  al., 1998, 
2001; Elorza et  al., 2003), being Mdm2 a key E3 ligase involved 
in GRK2 proteolysis by the proteasome (Salcedo et  al., 2006). 
While regulation of stability seems to be  the main pathway 
FIGURE 1 | Molecular mechanisms of GRK2 activation and functionality relevant for the design of therapeutic strategies. GRK2 dosage has been altered in different 
preclinical models by using global or tissue-specific Cre-based depletion methodologies, siRNA technology, and also adenoviral and lentiviral transfer of GRK2-specific 
silencing constructs. In addition to small molecule and aptamer compounds that able to keep the kinase in inactive conformations, other strategies to block GRK2 
activation are based on the use of peptide sequences, fragments of its domains (βARKct), or small molecules (gallein, M119) in order to interfere with known GRK2 
activators as GPCR and Gβγ subunits. Other strategies may be based on the interaction of GRK2 with inhibitory proteins such as RKIP, S-nitrosylation of specific 
residues in the catalytic domain, or via modulation of GRK2 phosphorylation at residues relevant for determining the substrate repertoire of GRK2. See text for details.
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controlling GRK2 dosage, changes in mRNA transcription have 
also been reported in several pathological conditions, including 
hypertension, cardiac hypertrophy, and heart failure (Cannavo 
and Koch, 2018; Mayor et  al., 2018). However, relatively little 
is known about the mechanisms governing promoter activity 
and transcript stability of GRK2 or regarding the participation 
of miRNAs in GRK2 regulation, although miR-K3, a Kaposi’s 
sarcoma-associated herpesvirus (KSHV) miRNA, has been shown 
to repress GRK2 expression (Hu et al., 2015). A better knowledge 
of the mechanisms of modulation of GRK2 protein turnover 
and expression would help to design strategies to control GRK2 
dosage in pathological settings.
PHYSIOPATHOLOGICAL ROLES  
OF GRK2
GRK2 levels and activity are reportedly increased in different 
tissues of patients and/or in preclinical models in cardiovascular 
and metabolic disease-related contexts, contributing to disease 
progression by a variety of mechanisms, whereas GRK2 inhibition 
plays a protective role (Figure 2).
GRK2 in Cardiac Function and Pathology
GRK2 has a relevant role in the control of cardiac function 
and enhanced GRK2 expression has been reported in the failing 
human hearts and in experimental models of heart failure 
(HF) in contexts of both chronic hypertensive and ischemic 
disease. Accordingly, genetic GRK2 deletion or pharmacological 
inhibition is cardioprotective in animal models recapitulating 
these pathological settings [reviewed in (Penela et  al., 2006; 
Schumacher et  al., 2015; de Lucia et  al., 2018)].
Cardiac GRK2 mRNA and/or protein levels appear to 
be  increased in HF patients with dilated or ischemic 
cardiomyopathy as a consequence of sympathetic nervous system 
hyperactivity in such situations. Augmented release of 
catecholamines is an early compensatory mechanism triggered 
in response to myocardial damage and dysfunction in order 
to maintain cardiac output via β-adrenergic-mediated effects 
in cardiac contractility. Enhanced GRK2 levels in the heart in 
FIGURE 2 | Cardiovascular and metabolic disease-related contexts with increased GRK2 levels and effects of interfering GRK2 expression or functionality. 
Enhanced GRK2 levels have been reported in different tissues and cell types of patients and/or preclinical models of the indicated situations associated with 
cardiovascular and metabolic diseases. On the other hand, interfering GRK2 functionality in these settings in preclinical models can modulate different relevant 
cellular processes implicated in disease development and progression. See text for details.
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such situations would initially help compensate such β-adrenergic 
overdrive. However, continued adrenergic stimulation and cardiac 
GRK2 overexpression are maladaptive, finally leading to decreased 
contractility and altered cardiac cell metabolism and survival 
(Ungerer et  al., 1993; Sato et  al., 2015b; de Lucia et  al., 2018). 
Of note, in such contexts, the increased catecholamine release 
in adrenal glands triggers a “damaging cycle” by fostering GRK2 
upregulation also in the chromaffin adrenal cells, which prevents 
α2-adrenergic receptor-mediated feedback inhibition of adrenal 
catecholamine secretion thus perpetuating the neurohormonal 
overdrive and boosting GRK2- and β-adrenergic-mediated 
maladaptive actions (Lymperopoulos et  al., 2007, 2016; 
Lymperopoulos, 2011).
Although such long-term maladaptive increase in GRK2 
expression is well established in different experimental models, 
a decrease in GRK2 levels via proteasomal degradation has 
been reported in the subepicardial border and the infarct zone 
at 6 and 24  h after ligation of the coronary artery in dogs, 
and treatment with proteasome inhibitors shown to prevent 
GRK2 degradation and result in significant cardioprotection 
against malignant ventricular tachyarrhythmias (Yu et al., 2000, 
2005; Huang et  al., 2008). Therefore, a better knowledge of 
the time course of changes in cardiac GRK2 levels in pathological 
situations and its functional impact is required to better define 
the correct timing of therapeutic strategies targeting GRK2.
The functional role of GRK2  in cardiac tissue involves both 
modulation of GPCR and interactions with other signaling 
molecules. GRK2 overexpression in transgenic mice attenuates 
βAR signaling, whereas hemizygous GRK2 mice show an 
enhanced response to adrenergic agonists (Koch et  al., 1995; 
Rockman et  al., 1998). On the other hand, transverse aortic 
constriction and continued angiotensin II-mediated stimulation 
of Gq-coupled AT1 receptors cause increased GRK2 expression 
in the context of cardiac hypertrophy, and GRK2 has also 
been shown to modulate angiotensin II-mediated contraction 
by directly interacting with Gαq (Schumacher et  al., 2016). 
GRK2 may also regulate the functionality of other relevant 
cardiac GPCRs such as GLP-1, adiponectin, k-opioid, or purinergic 
receptors (Heusch, 2015; Wang et  al., 2015; Chen et  al., 2017; 
Mayor et  al., 2018).
In addition, GRK2 has emerged as an important modulator 
of cardiac insulin signaling, which is key for a balanced 
glucose and fatty acid metabolism in the heart and has 
cardioprotective features (Lucas et  al., 2015; Hullmann et  al., 
2016; Riehle and Abel, 2016). Increased GRK2 levels worsen 
glucose uptake after ischemic injury via IRS1 phosphorylation, 
whereas cardiac-specific GRK2 knockout mice show enhanced 
heart glucose metabolism (Ciccarelli et  al., 2011). Notably, a 
high fat diet (HFD) promotes cardiac GRK2 accumulation leading 
to impaired cardiac insulin sensitivity and reduced stimulation 
of the cardioprotective PI3K/Akt pathway, whereas this effect 
was prevented in 9-month-old hemizygous GRK2+/− mice, 
which showed a preserved insulin-dependent downstream 
signaling and an overall cardioprotective gene expression 
reprogramming (Lucas et al., 2014, 2015). Therefore, situations 
of neurohumoral activation and of obesity/insulin-resistance 
converge in promoting cardiac GRK2 upregulation, which emerges 
as a potential factor linking insulin-resistant pathological conditions 
and heart failure. In this regard, in a long-term obesity-
induced cardiac remodeling model, reduced GRK2 dosage 
in hemizygous GRK2+/− mice preserves the activation of 
the PKA/CREB and AMPK pathways downstream of different 
cardiac GPCR, maintains the expression of key cardioprotective 
metabolic enzymes and mitochondrial proteins, and thus 
safeguards these animals from obesity-induced cardiomyocyte 
hypertrophy, fibrosis, and steatosis (Lucas et  al., 2016). Also 
supporting a key role for GRK2  in insulin/GPCR pathways 
crosstalk, hyperinsulinemia associated to type 2-diabetes fosters 
β2AR phosphorylation leading to decreased βAR-regulated 
cardiac contractility, in a manner dependent on IRS1/IRS2, 
PKA, and GRK2 activity (Fu et  al., 2014), this effect being 
potentiated upon GRK2 over expression and prevented upon 
GRK2 inhibition (Wang et  al., 2017a).
These data point to a scenario in which GRK2 levels act 
as an integrating hub controlling both myocardial contractile 
function and cardiac metabolism. In fact, GRK2 levels appear 
to control such key aspects of cardiac function by molecular 
mechanisms additional to those already described. GRK2 localizes 
to cardiac mitochondrial fractions upon ERK1/2 phosphorylation 
in ischemic contexts, which favors GRK2/Hsp90 interaction and 
mitochondrial targeting. Upregulated mitochondrial GRK2 seems 
to be  required for mitochondrial-dependent death pathway 
signaling and facilitates calcium-induced opening of the 
mitochondrial permeability transition pore (Chen et  al., 2013). 
Moreover, the mitochondrial GRK2 pool appears to enhance 
superoxide levels and to diminish substrate utilization for energy 
production (Sato et  al., 2015a), whereas enhanced kinase levels 
in cardiomyocytes potentiate oxidative stress and apoptosis 
(Theccanat et  al., 2016) and contribute to impaired fatty acid 
uptake and oxidation (Pfleger et  al., 2018). However, in other 
cell models, a positive role for GRK2 in mitochondrial biogenesis 
and ATP generation (Fusco et al., 2012) and a potential protective 
effect of GRK2 shuttling to the mitochondria by modulating 
fusion and recovery of this organelle in response to acute cell 
damage have been suggested (Sorriento et  al., 2014; Franco 
et  al., 2018). Therefore, more research is needed to define the 
role of mitochondrial GRK2  in both homeostasis and specific 
pathological contexts. Additionally, in transgenic models displaying 
increased cardiac GRK2, an impairment of the cardioprotective 
eNOS pathway and reduced NO bioavailability is observed in 
cardiac cells, thus promoting increased myocardial injury in 
ischemia/reperfusion mice models by mechanisms involving 
mutual inhibition of GRK2 and eNOS (Huang et  al., 2013).
It is also worth noting that altered GRK2 levels in other 
cardiac cell types may contribute to heart dysfunction. An 
increase in GRK2 expression predominantly in endothelial cells 
was reported in the heart of rats 7  days after induction of 
myocardial infarction (Vinge et al., 2001). In addition, increased 
GRK2 levels in cardiac fibroblasts contribute to enhanced 
collagen synthesis and fibrosis and appear to favor maladaptive 
remodeling upon ischemia/reperfusion injury (Woodall et  al., 
2016), whereas inhibition of the Gβγ-GRK2 axis limits 
pathological myofibroblast activation after myocardial ischemia 
(Travers et  al., 2017).
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On the other hand, augmented GRK2 levels have been 
reported in peripheral blood samples in HF (Rengo et  al., 
2016) or acute myocardial infarction (Santulli et  al., 2011) 
patients, but the potential pathophysiological impact of such 
altered dosage remains to be  determined. Early and balanced 
recruitment of cells of the innate immune system (monocytes/
macrophages, mast cells, and neutrophils) is key for initiating 
cardiac remodeling and repair after heart injury (Frangogiannis, 
2014). Given the reported ability of GRK2 to regulate 
inflammatory responses and NFκB signaling (Sorriento et  al., 
2015; Steury et  al., 2017) as well as chemokine and other 
GPCR involved in leukocyte trafficking (Grisanti et  al., 2016), 
it is tempting to suggest that altered GRK2 levels in circulating 
cells may modulate the timing or intensity of the immune 
response triggered upon cardiac injury.
In sum, enhanced cardiac GRK2 dosage in pathological 
conditions is expected to simultaneously alter key pathways 
controlling cardiac physiopathology, including βAR and 
GPCR signaling, mitochondrial function, cardiac insulin 
signaling, and also metabolic and survival cascades or NO 
bioavailability, ultimately contributing to altered contractility, 
metabolic and energetic derangement, pathological gene 
expression reprogramming, maladaptive myocardial remodeling, 
and progression to heart failure.
These data put forward cardiac GRK2 inhibition as an 
attractive therapeutic strategy. In fact, cardiomyocyte-specific 
knockout of GRK2  in mice protects (Fan et  al., 2013) injury 
promoted by ischemia/reperfusion while damage is increased 
in cardiac transgenic mice overexpressing the kinase (Brinks 
et al., 2010), by mechanisms reportedly related to proapoptotic 
signaling linked to increased GRK2 mitochondrial pools. 
Moreover, GRK2 deletion 10 days after myocardial infarction 
(Raake et  al., 2008) or treatment with the GRK2 inhibitor 
paroxetine (see below) started 2  weeks after injury 
(Schumacher et  al., 2015) improves cardiac function and 
reduces adverse ischemic remodeling in mice. On the other 
hand, adenoviral-mediated delivery of the C-terminal region 
of GRK2 (βARKct) also has a protective effect in heart 
failure and acute myocardial infarction settings in murine 
and pig models (reviewed in Sato et  al., 2015b; Cannavo 
and Koch, 2018; de Lucia et  al., 2018) by mechanisms likely 
involving prevention of the activation of GRK2 by Gβγ 
subunits (Rudomanova and Blaxall, 2017b).
A better knowledge of the interactome of GRK2 and its 
modulation in the different cardiac cell types, of the molecular 
mechanisms and stimuli leading to increased GRK2 expression 
in settings of cardiac hypertrophy, ischemia/reperfusion, and 
post-infarction remodeling, and of the detailed temporal pattern 
of such changes would help to fine-tune the therapeutic strategies 
targeting this protein.
Vasculature
Vascular tone is regulated by vasodilator and vasoconstrictor 
factors mainly released by endothelial cells (EC) in response 
to mechanical or chemical stimuli. The imbalance between 
these substances leads to the endothelial dysfunction and/or 
altered vasoconstrictor responses observed in cardiovascular 
diseases. Among the different systems involved in vascular 
dysfunction are effectors of the sympathetic nervous and renin 
angiotensin systems, endothelin-1, and prostanoids that can 
signal through specific GPCR leading to reduced NO 
bioavailability and endothelial dysfunction by different 
mechanisms (Vanhoutte, 2018). These include, among others, 
modulation of the expression/activity of the endothelial NO 
synthase (eNOS), eNOS uncoupling due to substrate or cofactor 
deficiency, and alterations in eNOS activation through its 
phosphorylation by different kinases including the PI3K/Akt 
pathway (Vanhoutte et al., 2016; Vanhoutte, 2018). In addition, 
activation of many GPCRs controls vascular smooth muscle 
cells (VSMC) proliferation and migration as well as extracellular 
matrix deposition (Althoff and Offermanns, 2015).
Changes in GRK2 levels and/or activity can mediate important 
effects in vascular function and structure that have been 
classically explained by GRK2-dependent desensitization of 
different GPCRs (Brinks and Eckhart, 2010) such as angiotensin 
II (AngII), endothelin, or adrenergic receptors. Overall, different 
studies describe that a partial deficiency or inhibition of GRK2 
differentially alters vasoconstrictor responses to GPCR agonists 
(Rainbow et al., 2018), while vasodilator effects seem to be more 
generally increased. This apparently preferential desensitization 
by GRK2 of vasodilation versus vasoconstriction signaling has 
been invoked to explain the effect of upregulated GRK2 levels 
seen in human and murine hypertension (Eckhart et  al., 2002; 
Izzo et  al., 2008; Cohn et  al., 2009; Santulli et  al., 2013). In 
this line, studies in sinusoidal endothelial cells from injured 
livers demonstrated that Akt physically interacts with GRK2, 
which inhibits Akt activation and NO production (Liu et  al., 
2005). Thus, the increased expression of GRK2 observed in 
vessels from different mouse models of vascular or metabolic 
diseases (Taguchi et  al., 2011a, 2012b) can be  an underlying 
factor that decreases NO bioavailability and contributes to 
endothelial dysfunction (Lucas et al., 2015). For instance, chronic 
AngII treatment of C57Bl6 mice upregulates GRK2  in vessels, 
leads to inhibition of the Akt/eNOS pathway, and thus reduces 
NO production both basally and after AngII-infusion that 
finally results in endothelial dysfunction (Avendano et al., 2014). 
Interestingly, some of these differences appear to be  gender-
dependent (Taguchi et  al., 2012a). More importantly, GRK2 
inhibition or partial GRK2 deletion improved the endothelial 
dysfunction observed in obese/diabetic (Taguchi et  al., 2011b, 
2012c, 2013) or hypertensive (Avendano et  al., 2014) animal 
models by restoring the impaired Akt/eNOS pathway and NO 
availability in a process in which glucose homeostasis may 
be  implicated (Taguchi et  al., 2017). Overall, these studies 
consolidate GRK2 as a genuine negative modulator of NO 
bioavailability. However, as mentioned above, recent evidence 
suggest that a reciprocal negative regulation exists between 
GRK2 and NO with increased NO bioavailability being an 
endogenous inhibitor of this kinase by S-nitrosylation of Cys340 
of GRK2 [reviewed in (Cannavo and Koch, 2018)] pointing 
to a feedforward relationship between NO and GRK2. 
Interestingly, some recent reports have described that a more 
profound and global GRK2 knockdown may be  detrimental 
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due to enhanced renin- and AT1R-mediated reactive oxygen 
species (ROS) production that can cause renal damage (Tutunea-
Fatan et  al., 2018) and the development of hypertension with 
age (Tutunea-Fatan et al., 2015). Together, these findings suggest 
that partial or local rather than generalized GRK2 targeting 
might be considered when increased NO levels and a correction 
of endothelial dysfunction need to be  achieved.
Vessels from patients or animal models of obesity and 
metabolic syndrome frequently display hypertrophic remodeling 
with particular differences depending on the vascular bed 
(Briones et  al., 2014). This vascular remodeling seems to 
be  influenced by hemodynamic factors such as hypertension 
and most often can be reversed at least in part by pharmacological 
blockade of the renin-angiotensin-aldosterone or endothelin 
systems (Briones et al., 2014). The role of GRK2 in the structural 
and mechanical alterations in vessels is only beginning to 
be  elucidated and might depend on the cell-specific location 
of GRK2 or on the experimental model. Thus, a partial overall 
GRK2 deletion prevents vascular hypertrophy and increased 
vessel stiffness observed in the AngII-induced hypertension 
model (Avendano et  al., 2014). However, endothelial-specific 
depletion of GRK2  in Tie2-CRE/GRK2(fl/fl) mice leads to 
structural abnormalities that were reverted by a ROS scavenger 
(Ciccarelli et  al., 2013), and an impaired angiogenic response 
with immature vessels was observed in these animals and in 
GRK2+/− mice (Rivas et al., 2013). The mechanisms responsible 
for these GRK2-mediated effects in vascular structure and 
development are not fully understood, but GRK2 and β-arrestins 
participate in the modulation of arterial smooth muscle purinergic 
signaling (Morris et al., 2011) and of agonist-stimulated VSMC 
migration through activation of proliferative and promigratory 
MAPK such as ERK1/2 (Morris et  al., 2012). Conversely, a 
negative role for GRK2  in VSMC proliferation has also been 
shown (Peppel et  al., 2000; Guo et  al., 2009). In sum, the 
results presented in this section highlight a potentially novel 
strategy for the regulation of vascular dysfunction through 
GRK2 targeting.
Adipose Tissues
As a combination of different repositories, the adipose tissue 
can be  considered a multi-depot organ located mainly in two 
compartments: subcutaneous and visceral (Cinti, 2005). Adipose 
depots can also be differentiated into white and brown adipose 
tissue according to their specific physiological roles and 
morphological appearance.
White Adipose Tissue
Classically considered as a mere energy store, the white adipose 
tissue (WAT) forms a large organ devoid of a specific shape 
and size but with a large physiological plasticity (Cinti, 2012) 
and important endocrine and homeostatic functions (Trayhurn 
and Beattie, 2001). Structural and/or functional variations in 
WAT together with changes of its fat load are key features 
correlating with metabolic alterations (Primeau et  al., 2011; 
McLaughlin, 2012). In this regard, insulin is a critical regulator 
of the most important aspects of adipocyte biology. This hormone 
promotes triglyceride storage within WAT by promoting adipocyte 
differentiation and by stimulating glucose uptake and triglyceride 
synthesis while inhibiting lipolysis Thus, maintaining the integrity 
of insulin signaling is crucial for an adequate physiological 
role of adipocytes.
In this line, GRK2 has been unveiled as an important regulator 
of insulin signaling in different insulin-target tissues including 
WAT. In fact, GRK2 hampers insulin-mediated glucose uptake 
in 3T3L1 adipocytes by several mechanisms including interfering 
with Gαq/11 (Usui et  al., 2005) and sequestering IRS1  in a 
process that is independent of its kinase activity (Garcia-Guerra 
et al., 2010). On the other hand, GRK2 can also act as a modulator 
of overall adiposity and fat mass accretion [reviewed in (Mayor 
et al., 2011)]. Aged or HFD-fed GRK2+/− mice show a decreased 
size of white adipocytes (Garcia-Guerra et al., 2010) and a reduced 
expression of enzymes involved in lipogenesis (Vila-Bedmar et al., 
2012). Moreover, tamoxifen-induced GRK2 depletion during a 
HFD reduces adipose WAT mass and adipocyte size and increases 
markers of lipolysis as well as the ex vivo and in vivo lipolytic 
response of this tissue even after overweight and IR have already 
been established (Vila-Bedmar et al., 2015). Furthermore, insulin 
resistance, glucose levels, and GRK2 expression emerge as strongly 
associated variables in a homeostasis model assessment of adipose-
derived stem cells obtained from lean and obese human patients 
(Ceperuelo-Mallafre et  al., 2014). These data suggest that GRK2 
can play a relevant role in the establishment of insulin-resistant 
states in murine and human WAT and that these states can 
be overturned by genetic ablation of GRK2, thus putting forward 
that interfering with GRK2 could be  a good strategy to revert 
the damaging effects of a dysfunctional WAT.
Brown Adipose Tissue
Heat production through non-shivering thermogenesis occurs 
chiefly in the brown adipose tissue (BAT) in different organisms 
including humans. Therefore, BAT represents a natural target 
for increasing energy expenditure since thermogenesis relies 
on energy dissipation to maintain body temperature. This 
process depends on the specific expression in brown adipocytes 
of the uncoupling protein UCP1, a mitochondrial inner 
membrane protein that promotes dissipation of nutrient-derived 
energy in the form of heat [reviewed in (Cannon and Nedergaard, 
2004)]. Therefore, although insulin regulates metabolism in 
both brown and white adipocytes, the role of both tissues in 
energy storage and utilization is quite different. Unlike WAT, 
BAT accumulates lipids not as a store for the excess of energy 
but as a source of molecules to be  oxidized in mitochondria 
when thermogenesis is activated to produce heat (Guillen et al., 
2013). Given the role of BAT as a sink for draining and 
oxidation of glucose and triglycerides from blood, enhancing 
BAT development/activity or promoting browning of WAT may 
contribute to a reduction in body weight and to the improvement 
of glucose tolerance.
GRK2 appears to play an important role in both BAT 
function and architecture, as well as in brown adipocyte 
differentiation (Vila-Bedmar et  al., 2012). In keeping with this 
notion, the decreased age-induced weight gain observed in 
adult GRK2+/− mice seems to be  due, at least in part, to a 
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preserved function of BAT in these animals. Accordingly, GRK2 
hemizygous mice display higher energy expenditure and lower 
respiratory exchange ratio. This correlates with morphology of 
GRK2+/− BAT that is more consistent with an efficient 
thermogenic function (Vila-Bedmar et  al., 2012). Moreover, 
decreasing GRK2 during a HFD through tamoxifen-induced 
genetic depletion prevents fat accumulation and increases the 
expression of fatty acid oxidation and thermogenic markers 
within BAT (Vila-Bedmar et  al., 2015). Furthermore, BAT 
explants of these animals showed an enhanced ex vivo lipolytic 
response to the β-adrenergic agonist isoproterenol. Altogether, 
these data point to an increased capacity for fatty acid metabolism 
in mice with low GRK2 levels and might explain the absence 
of lipotoxicity observed in these animals despite the increased 
free fatty acid availability caused by enhanced WAT lipolysis. 
They also point toward GRK2 inhibition as a potential tool 
for the enhancement of brown fat activity that could have 
additive effects to the function of this kinase in the regulation 
of insulin signaling.
Liver
The liver plays a central role in the regulation of metabolic 
homeostasis. For instance, the synthesis of glucose from 
non-carbohydrate sources during nutrient deprivation or fasting 
occurs in the liver through gluconeogenesis. When refeeding 
allows glucose levels to rise, hepatic gluconeogenesis is 
inactivated and the liver stores ingested carbohydrates as 
glycogen. Insulin signals restore the normoglycemia after a 
meal chiefly by regulating these two processes, gluconeogenesis 
and glycogen synthesis, in the liver. However, in metabolic 
disorders, the liver develops IR leading to increased glucose 
output and decreased glucose clearance leading to sustained 
hyperglycemia that can bring about pathological consequences 
(Czech, 2017).
One of the most important complications related to hepatic 
IR is non-alcoholic fatty liver disease (NAFLD) that expands 
from simple steatosis to non-alcoholic steatohepatitis (NASH). 
NASH involves the establishment of inflammation, fibrosis, and 
cirrhosis in the liver, which can originate end-stage liver failure 
and eventually evolve into hepatocellular carcinoma (Malaguarnera 
et  al., 2009). One major underlying cause of NASH is the 
development of hepatic IR, a feature that upregulates the levels 
of hepatic lipogenic transcription factors and underlies triglyceride 
accumulation in the liver thus causing hepatic steatosis 
(Malaguarnera et al., 2009; Smith and Adams, 2011; Cusi, 2012).
Interestingly, chronic insulin stimulation increases GRK2 
levels and decreases insulin receptor expression in mouse liver 
FL83B cells (Shahid and Hussain, 2007). This is in accordance 
with the absence of an activation of glycogen synthesis following 
the defective phosphorylation status of IRS1 observed in these 
cells (Shahid and Hussain, 2007). In keeping with these results, 
our group has shown that GRK2 levels were increased in the 
liver of mice fed a HFD (Garcia-Guerra et  al., 2010) or a 
methionine and choline-deficient diet (MCD), as a mouse 
model of NASH, and also in human patients diagnosed with 
NASH (Cruces-Sande et  al., 2018). Also, Sprague-Dawley rats 
fed a HFD present increased hepatic plasma membrane-associated 
GRK2 (Charbonneau et al., 2007). Interestingly, insulin-mediated 
signaling is maintained in the liver of GRK2 hemizygous mice 
under different IR-inducing conditions (Garcia-Guerra et  al., 
2010). Moreover, decreasing GRK2 during a HFD by means 
of tamoxifen-induced genetic depletion prevents hepatic steatosis 
and shifts the expression of proinflammatory toward anti-
inflammatory markers in the livers of these animals (Vila-
Bedmar et  al., 2015). These data uncover a role for GRK2  in 
the regulation of fat accumulation and inflammation in the 
liver. A very recent study also reveals that mice partially 
deficient for GRK2 are resistant to the development of NASH 
independently of obesity and IR (Cruces-Sande et  al., 2018). 
These animals were diagnosed with simple steatosis and not 
NASH after an MCD feeding and present lower inflammation, 
a better handling of ER stress, preserved autophagy, and more 
active processes of mitochondrial biogenesis and dynamics 
after the MCD.
ORGAN CROSSTALK IN 
CARDIOVASCULAR AND METABOLIC 
DISEASES
It is worth noting that cardiovascular and metabolic diseases 
are often present as co-morbidities and the tissues and organs 
involved in these pathological situations are highly interconnected. 
Type-2 diabetes and obesity enhance the chance of developing 
heart failure independently of other risk factors (Riehle and 
Abel, 2016) by mechanisms involving altered systemic 
neurohormonal, metabolic, hormonal, and inflammatory mediators 
(enhanced catecholamine and angiotensin levels, hyperinsulinemia, 
hyperglycemia, augmented circulating free fatty acids (FFA), or 
altered adipokine and cytokine secretion), contributing to altered 
cardiac metabolism and signaling, and fostering the development 
of diabetic cardiomyopathy (Woodall et  al., 2014; Jia et  al., 
2016). NAFLD has also been linked to increased risk of 
cardiovascular disease as a result of aberrant glucose, fatty acid 
and lipoprotein metabolism, oxidative stress, altered cytokine 
secretome, and endothelial dysfunction (Bhatia et  al., 2012). In 
addition, emerging evidence points to additional crosstalk 
mechanisms from the heart to peripheral organs. The injured 
and remodeling heart secretes a variety of inflammatory cytokines 
and metabolic and lipid mediators that can in turn impact the 
functions of the kidney, adipose tissue, or the liver [reviewed 
in (Baskin et  al., 2014; Fujiu et  al., 2017)], thus perpetuating 
a pathological cycle among the heart and key metabolic tissues. 
The fact that different pathological triggers converge in promoting 
GRK2 upregulation in many of the tissues involved in such 
crosstalk reinforces the notion that simultaneous GRK2 inhibition 
in all the tissues implicated in a given pathology might have 
a synergic beneficial effect.
STRATEGIES TO TARGET GRK2
Genetic inhibition has been, so far, the most successful strategy 
to achieve a downregulation of GRK2 protein/function as a 
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tool to demonstrate the participation of this kinase in 
physiopathological processes and as a proof of concept of its 
potential use as a therapeutic target. A mounting amount of 
evidence describes the effects of GRK2 downregulation either 
in mouse models deficient for GRK2, tissue-specific and 
Cre-based inducible depletion, siRNA technology both in mice 
and in cultured cells, and also adenoviral and lentiviral transfer 
of GRK2-specific silencing or overexpression constructs. This 
has served to establish GRK2 as a target to tackle with important 
diseases, as recently reviewed elsewhere for cardiac (Cannavo 
et al., 2018), metabolic (Mayor et al., 2018), vascular (Schumacher 
and Koch, 2017), renal (Rudomanova and Blaxall, 2017b), and 
tumoral (Nogues et  al., 2017) pathological contexts.
The genetic approaches to downregulate GRK2 levels, 
although not translatable to the clinical practice, can thus 
provide very useful information about the feasibility and 
potential drawbacks of GRK2 as a therapeutic target. In this 
regard, one particularly interesting model is the use of global 
hemizygous GRK2 mice, which would bona fide mimic the 
likely partial effects of pharmacological systemic inhibition of 
GRK2 and show the integrated effects of GRK2 inhibition in 
different tissues and cell types (Avendano et  al., 2014; Lucas 
et  al., 2014). On the other hand, inducible global GRK2 
deletion models can help to determine whether systemic GRK2 
downregulation can not only prevent but also revert certain 
diseases such as reported in the context of insulin resistance, 
overweight, and glucose (Vila-Bedmar et  al., 2015). These 
approaches can also inform of potential disadvantages or 
possible side effects of GRK2 inhibition and differentiate 
between effects due to inhibition of kinase activity alone (by 
using kinase activity inhibitors as detailed below) or also to 
scaffold functions of this protein (only altered when decreasing 
protein levels). For instance, a recent publication suggests that 
a global GRK2 downregulation by using a silencing construct 
under the control of the U6 mouse polymerase III promoter 
may have detrimental outcomes in kidney function and 
development (Tutunea-Fatan et al., 2018), thus suggesting that 
therapeutic strategies that target GRK2 activity, not expression, 
could be  safer in particular for the treatment of hypertension 
(Tutunea-Fatan et  al., 2015).
More specific targeting strategies such as those reducing 
GRK2 expression in particular cell types can also provide 
useful information about possible cell type-specific drawbacks 
of chronic GRK2 inhibition. For instance, a reduction of 
GRK2  in myeloid cells increases the risk of septic shock in 
mouse models (Patial et  al., 2011), although myeloid-specific 
GRK2 does not alter immune cell infiltration to the primary 
site of infection or bacterial clearance and does not significantly 
affect mortality in a cecal ligation puncture model of 
polymicrobial sepsis (Parvataneni et  al., 2011). In microglia, 
GRK2-targeting can transform acute inflammatory pain into 
chronic hyperalgesia (Eijkelkamp et  al., 2010), and decreased 
GRK2 levels in endothelial cells can cause reduced maturation 
of vessels (Rivas et  al., 2013) and defects in vascular function 
and structure (Ciccarelli et  al., 2013). In sum, although a 
reduction of GRK2 protein and/or activity is as a clear target 
for intervention in cardiovascular and metabolic pathologies, 
care should be  taken when exploring the consequences of 
downregulating GRK2 in other diseases involving renal, myeloid, 
or endothelial cells.
In addition to genetic approaches, a variety of other potential 
strategies to inhibit GRK2 functions are being developed based 
on the structural features and mechanisms of regulation of 
this kinase and are described in the following sections.
Small Molecule Inhibitors of GRK2
The search for a potent and selective small molecule inhibitor 
of GRK2 has turned out to be  a difficult quest. The first 
described compounds able to bind and negatively impact 
GRK2 activity were polyanionic and polycationic compounds 
such as heparin (Benovic et  al., 1989). They were unable to 
cross the plasma membrane, but capable of inhibiting in vitro 
GRK2-dependent rhodopsin phosphorylation with IC50 values 
below μM.
It was not until the crystal structure of human GRK2  in 
complex with balanol, a fungal metabolite synthetized by 
Verticillium balanoides, was solved (Tesmer et  al., 2010) that 
the mechanism of action of ATP-competitive inhibition of 
GRK2 was better elucidated and used in the search of compounds 
with increased selectivity for this kinase relative to other protein 
kinases and GRK family members [reviewed in (Guccione 
et  al., 2016)]. The relative efficacy of balanol, as tested in in 
vitro kinase assays using tubulin and rhodopsin as substrates, 
showed certain selectively toward GRK2 and GRK3 (with 
IC50  in the low nM range for both isoforms) as compared 
with GRK5 and GRK7 with IC50 in the high nM range, similar 
to those reported for PKA (Tesmer et  al., 2010). Balanol binds 
to a semi-closed inactive conformation of GRK2 (as compared 
with PKA) that could be  exploited pharmacologically. Since 
balanol adopts different conformations when binding to GRK2 
and to PKA, selectivity for GRK2 could be  improved by 
designing molecules that adapt to the particular conformation 
of the catalytic site adopted by GRK2 when bound to this 
compound that could be  different for different GRK isoforms.
The Takeda Pharmaceutical Company also identified several 
heterocyclic compounds that bound and inhibited GRK2, and 
they were subsequently co-crystallized with GRK2-Gβγ (Thal 
et  al., 2011). Similar to balanol, these compounds (called 
CMPD101 and CMPD103A) stabilized GRK2  in a slightly 
closed non-catalytic conformation with a degree of closure 
that correlated with potency for each species. Their IC50 values 
in a rhodopsin phosphorylation assay were of 290  nM and 
54  nM, respectively (Thal et  al., 2011), although an IC50 value 
of 35  nM had been previously reported in the corresponding 
patent. CMPD103A and CMPD101 are remarkably more selective 
among GRK subfamilies than balanol since they inhibit GRK2 
and GRK3 (“GRK2 subfamily”) with IC50s in the nM rage 
for both isoforms (that share 92% identity in their kinase 
domain sequences), but do not have an effect on GRK1 or 
GRK5 isoforms when used in concentrations up to 125  μM 
(Thal et  al., 2011). However, they inhibited PKA with an IC50 
of 2  μM. Possibly because of bioavailability problems, these 
compounds have not yet reached clinical trials even when 
they show desensitization-blocking activity and good potency 
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in cellular assays [see (Rainbow et  al., 2018) as an example]. 
Through a high throughput screening identification strategy 
using Ulight TopoIIα as an artificial substrate and subsequent 
SAR-guided development, the same company has more recently 
developed a novel class of GRK2 inhibitors with selectivity 
toward isoforms GRK1, 5, 6, and 7, but showing equipotent 
inhibition of GRK3 (Okawa et  al., 2017). Crystal structures 
using human GRK2 show a ligand-binding pose and interactions 
similar to those previously observed (Thal et  al., 2011). The 
best performing compound was named 115  h, has an IC50 
for GRK2 of 18 nM, and blocks desensitization of the β-adrenergic 
receptor pathway in HEK293 cells, although these effects were 
shown only at 100  μM concentrations. The pharmacokinetic 
profile after oral administration was however not enough to 
show in vivo activity.
An emerging family of small molecules being developed 
as GRK2 inhibitors are based on the FDA-approved selective 
serotonin reuptake inhibitor (SSRI) paroxetine, which was first 
found to target GRK2  in an aptamer displacement assay (Thal 
et  al., 2012). Paroxetine stabilizes a unique conformation of 
GRK2 that misaligns the small and large lobes of this kinase 
and thus represents a unique scaffold for the design of more 
selective GRK2 inhibitors (Thal et  al., 2012; Homan and 
Tesmer, 2015). Even when the IC50 of paroxetine is in the 
μM range using the rhodopsin (≈20 μM) or tubulin (≈2 μM) 
in vitro phosphorylation assays, the selectivity toward other 
GRK isoforms was a great improvement. Paroxetine was 50 
to 60 times more potent toward GRK2 than toward GRK1 
and GRK5 and performed well in living cells with a 10- or 
40-fold selectivity over PKA and PKC, respectively (Thal et al., 
2012). Paroxetine was also shown to inhibit β-adrenergic 
receptor desensitization by blocking GRK2-mediated receptor 
phosphorylation and β-arrestin recruitment with an IC50 of 
≈6  μM (Guo et  al., 2017). In vivo, paroxetine has been 
described to improve LV function and structure and to reverse 
or even ameliorate several features related to cardiac dysfunction 
in a mouse model of myocardial infarct when compared with 
fluoxetine, a structural analog unable to inhibit GRK2 but 
with SSRI capacity (Schumacher et  al., 2015). Also, in a rat 
model of limb ischemia-reperfusion (I/R) injury, decreased 
GRK2 expression levels were found in ipsilateral neurons of 
the superior cervical ganglion. However, in mice treated with 
paroxetine, GRK2 expression was preserved after I/R, thus 
linking GRK2 binding/inhibition with the stabilization of the 
protein (Tang et  al., 2015). Moreover, in another rat model 
of collagen-induced arthritis, oral (gavage) administration of 
paroxetine showed in vivo effects by protecting the joints 
from inflammation and destruction by impairing T cell 
infiltration and activation (Wang et  al., 2017b). Cytokine and 
chemokine levels in serum and synovial tissues were also 
reduced, as were the populations of CD4+ and CD8+ effector 
T cells with increased differentiation of Treg cells and an 
induction of immune tolerance. Altogether, these results show 
that this drug can have pharmacological effects in murine 
models even when using enteral administration.
When a library of known kinase inhibitors from the Structural 
Genomics Consortium at Oxford University was screened, 
several compounds targeting GRK2 with structures resembling 
paroxetine were found (Homan and Tesmer, 2015). The most 
active compound showed an IC50 below μM in the tubulin 
phosphorylation assay and was 100–1,000 times more potent 
toward GRK2 over GRK1 and GRK5 (Homan and Tesmer, 
2015). A highly potent and selective GRK2 inhibitor called 
14as has been more recently identified from a set of paroxetine-
derivative compounds (Waldschmidt et  al., 2016). 14as has 
an IC50 for GRK2 of 30  nM, shows more than 230-fold 
selectivity over GRK1, GRK5, PKA, and ROCK1, and performs 
two orders of magnitude better than paroxetine in cardiomyocyte 
contractility assays, although no data relative to the possible 
inhibition of the GRK3 isoform are shown or discussed. 
Co-crystal structures of three of the synthesized paroxetine 
derivatives revealed the establishment of hydrogen bonds that 
make GRK2 adopt a more open conformation relative to 
that achieved with other inhibitors, which probably underlies 
the high selectivity of these compounds. More interestingly, 
pharmacokinetic data indicate that its plasma concentration 
in mice after a single intraperitoneal administration is above 
its IC50 for over 7  h.
The molecule GSK180736A, a compound structurally similar 
to paroxetine that had been developed as a ROCK1 inhibitor, 
was shown to co-crystallize in the active site of GRK2 and 
is a potent and selective inhibitor of GRK2 with an IC50 of 
770  nM and more than 100-fold selectivity over other GRK 
isoforms. This molecule was used to develop a library of hybrid 
inhibitors containing some features from the Takeda compounds, 
namely occupation of the hydrophobic binding site in the 
kinase domain of GRK2, together with others from the 
GSK180736A molecule (Waldschmidt et  al., 2016). From this 
library, inhibitors that are highly selective for GRK2 as well 
as potent for both GRK2 and GRK5 emerged. In particular, 
the compound called 12n (CCG-224406) showed an IC50 of 
130  nM for GRK2 and, remarkably, more than 700-fold 
selectivity over GRK1 and GRK5, although no comparison 
using GRK3 is shown in this study. Emerging from other 
two classes of GRK2-selective inhibitors, namely GSK180736A 
and paroxetine, a molecular design initiative led to the creation 
of a set of new hybrid compounds in which the benzodioxole 
ring of paroxetine was exchanged for an indazole (indazole-
paroxetine hybrids) (Bouley et  al., 2017). Crystal forms from 
these hybrid molecules showed that they not only form stronger 
interactions with the hinge of GRK2 but also stabilize a distinct 
conformation, compared with paroxetine analogs, of its kinase 
domain. Therefore, the binding modes of these two families 
of compounds to the active site of GRK2 are similar, but 
they use two different hinge-binding moieties: indazole and 
benzodioxole. Among them, the CCG224061 compound presents 
a 20-fold increase in potency for GRK2 (IC50 of 66  nM) 
over paroxetine. However, it also shows increased activity 
against GRK1 and 5, PKA, and ROCK1 relative to the latter 
compound, and the results relative to GRK3 inhibition are 
not shown. So, the indazole-paroxetine analogs were more 
potent than benzodioxole derivatives, however at the cost of 
poorer selectivity, and possibly with a particular pharmacokinetic 
profile that may include renal clearance.
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A very recent study has utilized some of the most active 
among the formerly presented GRK2 inhibitors to test GRK2-
mediated desensitization of different arterial vasoconstrictor 
stimuli using ex vivo approximations (Rainbow et  al., 2018). 
Paroxetine, Takeda’s CMPD101, and two amide derivatives 
of GSK180736A (Waldschmidt et al., 2016) termed CCG215022 
and CCG224063 were used. Each of these compounds attenuated 
desensitization toward angiotensin II- or UTP-mediated 
contractile responses in myograph assays using rat arterial 
rings, as well as in P2Y2 and H1 histamine-mediated PLCβ 
signaling assays, in MSMC and ULTR cells with an IC50  in 
the low μM range (CCG224063  in the low nM). Altogether 
these and other functional and structural data are unveiling 
interesting molecular insights into the binding modes, kinase 
selectivity and pharmacological features of these families of 
GRK inhibitors.
Aptamers
Since the first RNA-based aptameric molecule that acts as an 
in vitro inhibitor of GRK2 activity was described (Mayer et  al., 
2008), several efforts to improve the potency and selectivity of 
this class of compounds have been pursued. This C13 molecule 
can stabilize a unique inactive conformation of GRK2 through 
different interactions within and outside the kinase domain and 
reorganizes certain regions of the kinase to establish interactions 
with its polyanionic phosphodiester backbone (Mayer et  al., 
2008). C13 achieves inhibition of rhodopsin phosphorylation 
by GRK2 at low nM concentrations with a 20-fold selectivity 
over GRK5, and no appreciable effects detected in a panel of 
14 other kinases (Mayer et  al., 2008). However, possible effects 
on a cellular setting have not yet been reported, and this is of 
particular concern since these types of molecules are not 
bioavailable when administered orally, may not be  stable inside 
the organism due to endoribonuclease-driven cleavage, and do 
not readily cross cell membranes. So, medicinal chemistry efforts 
should be  implemented in order to overcome these difficulties. 
They have however been successfully used as a method of 
selection to screen for better drug-like inhibitory molecules by 
aptamer displacement assays as described above.
Peptides
Other strategy to inhibit GRK2 activity is based on using 
peptide sequences to interfere with the interface between the 
kinase and its substrates or activators. Peptides corresponding 
to the β2-adrenergic receptor sequence reported to interact 
with GRK2 have been identified and subsequently modified 
(Benovic et al., 1990) to reduce kinase activity with an IC50  in 
the low μM range but showing varying degrees of selectivity 
among GRK isoforms. Interestingly, these peptides do not seem 
to interact broadly with the kinase domain of GRK2, but rather 
mimic the first intracellular loop of the receptor and establish 
only one contact point with the kinase. One of them shows 
activity in cells, impairs β2-adrenergic receptor desensitization, 
and enhances receptor signaling in the human A431 cell line. 
Other peptides derived from residues of the substrate-kinase 
interaction domain in GRK2 and GRK3 have been tested in 
several animal models of type 2 diabetes. Acylated glycine 
derivatives of these short peptides, such as KRX-683107 and 
KRX-683124, can reduce plasma glucose concentrations possibly 
through GRK2-mediated inhibition of insulin signaling and 
display a systemic antidiabetic effect (Anis et al., 2004; Cipolletta 
et  al., 2009). Another group of peptides was identified from 
a library of cyclic peptides designed using the GRK2 crystal 
structure, in particular the HJ loop inside the catalytic fragment 
of this kinase (Winstel et  al., 2005). Peptides 9b and 10d 
showed sub μM values of IC50 when tested in an in vitro 
rhodopsin phosphorylation assay with poor inhibition of GRK5 
and also presented activity in cells increasing basal and 
isoproterenol-stimulated cAMP production in HEK-293 cells 
overexpressing β2-adrenoreceptors.
Rational design of inhibitory peptides taking advantage 
of allosteric intramolecular interactions in GRKs has also 
been studied. For instance, N-terminal interactions as well 
as those emerging from an interface able to stabilize the 
closed active conformation of GRK2 (where receptor binding 
is proposed to activate GRK2) have been explored (Huang 
et  al., 2009). A peptide encompassing the first 14 residues of 
GRK2 decreases receptor phosphorylation with an IC50 of 
50 μM and at the same time enhances binding to phospholipids 
in what appears to be  a membrane-specific effect since it has 
no impact on the kinase activity toward the soluble substrate 
tubulin (Pao et  al., 2009).
Targeting the Gβγ-GRK2 Interface
The overexpression of a C-terminal fragment of GRK2 called 
GRK2ct or βARKct has been used as a strategy for GRK2 
inhibition, since this peptide should inhibit endogenous GRK2 
binding to Gβγ subunits and thus subsequent activation and 
translocation to the plasma membrane. Importantly, transgenic 
mouse models expressing βARKct constructs in the heart or 
adenoviral-mediated delivery of this construct in mice and 
pig models has shown to be  cardioprotective in both acute 
and chronic models of HF. Since these aspects have been 
recently reviewed (Rudomanova and Blaxall, 2017b; Campbell 
and Smrcka, 2018; Cannavo et  al., 2018), we  will only discuss 
herein potential future developments of this strategy and also 
some caveats regarding its functional impact.
Since viral-based gene delivery remains a daunting therapeutic 
methodology, efforts have been made to identify small molecule 
Gβγ interactors as a more viable alternative. Consequently, a 
virtual screening was performed on a National Cancer Institute 
chemical library to identify small molecules capable of binding 
Gβγ subunits, using as an assay the ability to displace Gβγ 
binding to SIGK, a peptide that has been co-crystallized with 
the dimer, and thus identifying a surface critical for Gβγ interaction 
with effectors (Campbell and Smrcka, 2018). Among those, one 
termed M119 (cyclohexanecarboxylic acid [2-(4,5,6-trihydroxy-
3-oxo-3H-xanthen-9-yl)-(9Cl)]) demonstrated high apparent 
affinity for Gβγ dimers and inhibited Gβγ-SIGK binding in 
vitro (Bonacci et  al., 2006). The compound M119 and its highly 
homologous and more stable analog gallein have been successfully 
used ever since both in cultured cells and in vivo. They are 
able to impair Gβγ-dependent GRK2 recruitment to the plasma 
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membrane in response to GPCR in different cell types. Moreover, 
they can hamper HF progression and improve cardiac function 
in different murine models where they halt fibrosis, hypertrophic 
gene expression, and inflammation and also reduce myocardial 
infarct size [reviewed in (Rudomanova and Blaxall, 2017a)]. 
Also, in this context, a group has recently reported the development 
of nanobodies that able to specifically inhibit Gβγ-dependent 
signaling (Gulati et  al., 2018).
It is worth noting that either GRK2ct or these new types 
of compounds would not only affect Gβγ-GRK2 activation but 
also block other Gβγ effectors downstream GPCR activation, 
which may cause off-target effects that need to be  considered 
when evaluating their therapeutic roles. Although the notion 
of selective delivery of Gβγ inhibitors to specific target tissues 
using viral-guided approaches is attractive, the possible clinical 
application of this kind of strategies faces many regulatory 
and technical issues that need to be  solved.
Emerging Strategies to Target GRK2 
Functionality
The in-depth characterization of GRK2 modulatory mechanisms 
and the identification in recent years of a variety of new cellular 
partners of this kinase help envisage novel targeting strategies 
based on processes that able to modulate GRK2 activity/
expression or to control specific functions of GRK2.
One type of approach is based on the modulation of GRK2 
activation and translocation to the plasma membrane. Similar 
to the already discussed inhibitory effect caused by disruption 
of the interaction between GRK2 and Gβγ subunits, the 
GRK2K567E/R578E mutation, which eliminates anionic phospholipid 
binding, also ablates receptor phosphorylation in cells (Carman 
et  al., 2000). In fact, efficient GRK2-mediated phosphorylation 
of activated GPCRs is dependent not only on its recruitment 
to the membrane by Gβγ subunits but also on the presence 
of phosphatidylinositol 4′,5′-bisphosphate (PIP2), a highly 
negatively charged lipid that not only helps recruit GRK2 but 
also orients the GRK2-Gβγ complex so that it is better able 
to phosphorylate activated GPCRs (Yang et al., 2016). This result 
is in contrast to what occurs with the GRK5 isoform, which 
adopts similar orientations on lipid bilayers whether or not 
they contain PIP2 (Yang et al., 2013). Therefore, isoform-selective 
inhibitors could be  designed to target the GRK2-phospholipid 
interaction and thus impair or redirect kinase activity toward 
defined substrates (e.g., soluble vs membrane bound). However, 
other studies have described the ability of phosphatidylserine 
(PS) to enhance GRK2-dependent phosphorylation of purified 
and reconstituted human m2 mAChR twofold to threefold while 
PIP2 strongly inhibited this reaction (DebBurman et  al., 1995). 
A possible explanation for this apparent discrepancy may be that 
neither Gβγ nor phospholipid interactions appear to play a 
major role in GPCR phosphorylation by GRK2 in vitro, possibly 
because high concentrations of the kinase and/or receptor can 
be  used to drive the reaction by mass action and thus lead to 
apparently contradictory results. Since this type of GRK2-plasma 
membrane in vivo interactions may not be accurately mimicked 
by in vitro systems, cell-based assays should be utilized in order 
to develop inhibitors based on the ability to interfere with 
lipid-dependent GRK2 activity. In any case, the fact that GRK2 
can be  considered a lipid-dependent kinase that may be  both 
upregulated and downregulated by phospholipids is an interesting 
feature that should not be  overlooked when suggesting new 
strategies for the regulation of its activity.
Other strategies may rely on the interaction of GRK2 with 
inhibitory proteins. RKIP, a multifaceted kinase modulator 
belonging to the conserved family of phosphatidylethanolamine-
binding proteins (PEBPs), is a small 21  kDa protein that able 
to regulate different signaling cascades and physiological processes. 
Phosphorylation of RKIP S153 by PKC appears to reorganize 
RKIP domains from a structure that binds and inhibits Raf-1 
into a conformation that associates and blocks GRK2 by binding 
to its N-terminus domain [reviewed in (Skinner and Rosner, 
2014)]. The inhibitory mechanism possibly requires RKIP dimer 
formation (Deiss et  al., 2012). In fact, overexpression of 
phosphomimetic (RKIPSK153/7EE) or dimeric (RKIPΔ143–146) RKIP 
peptides impairs phosphorylation of βARs by GRK2  in HEK293 
cells as detected using antiphosphoserine antibodies and also 
reduces GRK2-mediated rhodopsin phosphorylation in vitro (Deiss 
et  al., 2012). This study also shows that, at least in murine 
hearts, RKIP exists mostly in the S153-phosphorylated form and 
is thus predominantly bound to GRK2. In keeping with these 
data, interfering with RKIP by using specific antibodies, antisense, 
or RNAi plasmids enhances β-adrenergic signaling and its related 
contractile activity in cardiomyocytes (Lorenz et  al., 2003). 
Moreover, a modest overexpression of this protein in a transgenic 
mouse model produces an increase in cardiac contractility achieved 
by the simultaneous activation of the β1AR and β2AR subtypes 
of adrenergic receptors that is thus well-tolerated and persistent 
(Schmid et  al., 2015). These results open the possibility to use 
phosphorylated/dimeric RKIP to interfere with GRK2 functions 
in manners that could be  alternative or additive not only to 
the use of pharmacological GRK2 blockade but also to study 
new modes to achieve GRK2 functional downregulation. However, 
given the multifaceted role of this peptide in the control of 
other important kinases and pathways such as Raf, MEK, ERK, 
NFκB, GSK3β, among others, the selectivity of such strategies 
could be compromised and should be carefully examined. Finally, 
since other proteins such as caveolin1, actinin, or clathrin have 
been reported to bind to GRK2 and help maintain pools of 
inactive kinase at defined subcellular locations (Penela et  al., 
2010a), it is tempting to suggest that peptides derived from 
these regulatory partners (or small molecules mimicking those) 
may modify the catalytic activity of GRK2 and/or its subcellular 
distribution, thus selectivity affecting certain GRK2 substrates.
On the other hand, post-translational mechanisms activating/
inhibiting GRK2 or switching its partner repertoire could 
potentially be  used to interfere with GRK2-dependent cellular 
actions. As previously mentioned, GRK2 activity is regulated in 
opposing ways by different covalent modifications, such as those 
entailing tyrosine phosphorylation of GRK2 within the N-terminus 
and the RH domain, Ser670 phosphorylation, or cysteine-
nitrosylation in the catalytic domain. In particular, the 
S-nitrosylation of GRK2 limits the ability of this kinase to 
phosphorylate and desensitize the β2AR [recently reviewed in 
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(Cannavo and Koch, 2018)]. Accordingly, mice carrying a point 
mutation that substitutes the Cys340  in GRK2 for a serine 
(GRK2C340S) are less resistant to cardiac ischemic injury and 
lose responsiveness of their myocardium to increased or decreased 
NO (Huang et al., 2013). Moreover, a water-soluble N-nitrosamine 
able to nitrosylate GRK2 without generating NO has been shown 
to impair isoproterenol-mediated β2AR-desensitization via GRK2 
inhibition (Makita et al., 2013), thus providing a proof of concept 
that S-nitrosylation of GRK2 can be used as a therapeutic strategy.
Modulation of upstream kinases may also affect GRK2 
functionality in specific contexts. In particular, our group has 
reported that GRK2-mediated HDAC6 phosphorylation requires 
the previous phosphorylation of GRK2  in S670 (see previous 
sections), which apparently provokes a switch in GRK2 substrate 
usage (Lafarga et  al., 2012). GRK2S670A showed a noticeably 
reduced ability to phosphorylate HDAC6 as compared with 
WT GRK2 but did not show any defects in phosphorylating 
other GRK2 canonical substrates. This discovery opens the 
possibility for redirecting GRK2 activity toward defined substrate 
subsets. For instance, the use of compounds or cellular strategies 
that impair GRK2 phosphorylation in S670, such as ERK or 
CDK2 inhibitors, would either hamper or completely impair 
phosphorylation of HDAC6, and thus, GRK2-dependent effects 
downstream this deacetylase such as growth factor signaling, 
proliferation, and anchorage-independent growth of breast cancer 
cells (Nogues et  al., 2016). Although not specifically targeted 
to GRK2, such ERK or CDK2 inhibitors would indirectly rewire 
the GRK2 substrate repertoire by affecting its Ser670 
phosphorylation status. In this context, it would be  of interest 
to identify small molecules that differentially inhibit the activity 
of unphosphorylated and Ser670-phosphorylated GRK2 toward 
distinct cellular substrates. Other possible approach to impair 
GRK2 activity toward given substrates might be  the use of 
peptides (or small molecules) targeting the specific domains of 
GRK2 (or of its partner) involved in their recognition. Also, 
the substrate preference of GRK2 would depend on its particular 
subcellular localization in a given cellular setting. For instance, 
GRK2 can be  localized to the mitochondria by way of its 
interaction with Hsp90 proteins triggered by S670 phosphorylation 
(Chen et  al., 2013), and an important pool of microsomal-
bound GRK2 has been described in mouse liver and neuronal 
tissues as well as in cultured cells (Murga et  al., 1996). The 
consequences of the existence of different subcellular populations 
of GRK2  in terms of accessibility to defined substrates and the 
possibility that they may cause different final downstream effects 
are only beginning to be studied and should be fully elucidated.
A better knowledge of the stimuli and mechanisms controlling 
GRK2 expression may help to develop approaches to directly 
decrease GRK2 expression. As discussed in previous sections, 
diverse stimuli (catecholamines, angiotensin, high-fat diet) appear 
to converge in promoting enhanced GRK2 expression in different 
tissues and cell types in the context of given diverse cardiovascular 
and metabolic diseases. Thus, it is tempting to suggest that 
altering such stimuli would help to prevent pathological GRK2 
accumulation. In fact, beta-blockers as well as exercise have 
been described to reduce myocardial and vascular GRK2 levels 
[reviewed in (Hullmann et  al., 2016; Cannavo et  al., 2018; 
Mayor et al., 2018)]. On the other hand, the mostly unexplored 
field of GRK2 expression modulation by miRNAs may also 
identify tools for decreasing kinase levels in a tissue-specific 
way. Finally, the well-established degradation of GRK2 via the 
ubiquitin-proteasome pathway may also allow for strategies 
aimed at increasing GRK2 downregulation in particular cellular 
settings such as proteasome activators or the use of emerging 
techniques to target specific proteins for degradation, such as 
the use of the so-called Proteolysis Targeting chimeric molecules 
(PROTACs) (Gu et  al., 2018).
CONCLUSIONS
The GRK2 signaling hub is important in signaling pathways 
and processes related to very relevant cardiovascular pathological 
conditions (heart failure, cardiac hypertrophy, hypertension) and 
to diseases related to altered metabolic homeostasis (obesity 
metabolic syndrome, type 2 diabetes, NAFLD). These data along 
with the increased GRK2 expression reported in preclinical 
models of these pathologies and in samples from patients put 
forward this kinase as a promising therapeutic target. Moreover, 
the fact that these pathological conditions are frequently 
interconnected suggests that inhibiting GRK2 may have common 
beneficial effects when such situations concur as co-morbidities. 
In fact, genetic approaches have established the importance of 
GRK2 as a potential therapeutic target in some of these pathological 
processes. Strategies aimed to target GRK2 are beginning to 
yield some fruits, and several small molecules, peptides, and 
inhibitory constructs have been developed that effectively inhibit 
GRK2 activity and have been shown to display effects in cells 
and even in animal models. However, there are many challenges 
that need to be  addressed. In addition to attaining specificity 
toward other GRKs and other kinases and off-targets, GRK2 
inhibitors with acceptable in vivo potency and pharmacokinetic 
profiles are still awaited. On the other hand, the potential 
drawbacks of pathological effects of chronic GRK2 inhibition 
in defined cell types and tissues need to be  carefully considered 
in order to identify therapeutic windows. In addition, the 
identification of novel GRK2 substrates and partners and the 
existence of different subcellular pools open the possibility of 
specifically targeting the interaction of GRK2 with specific subsets 
of signaling proteins. A better knowledge of the dynamic structural 
events leading to GRK2 activation, of the interfaces involved 
in its interaction with given partners, and of the molecular 
mechanisms involved in the modulation of GRK2 expression, 
activity, and localization would help to develop or improve novel 
strategies for GRK2 inhibition. This would be  very important 
not only for advancing in the path for therapeutic application 
but as advanced research tools to dissect the precise contribution 
of GRK2 to physiological and pathological processes.
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